;PMID: 2064725
;source_file_807.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..106] = [t:36..106]
;2)section:[e:110..181] = [t:110..181]
;3)section:[e:185..276] = [t:185..276]
;4)sentence:[e:280..500] = [t:280..500]
;5)sentence:[e:501..916] = [t:501..916]
;6)sentence:[e:918..1058] = [t:918..1058]
;7)sentence:[e:1059..1468] = [t:1059..1468]
;8)sentence:[e:1470..1579] = [t:1470..1579]
;9)sentence:[e:1580..1711] = [t:1580..1711]
;10)sentence:[e:1712..1974] = [t:1712..1974]
;11)sentence:[e:1975..2187] = [t:1975..2187]
;12)section:[e:2191..2235] = [t:2191..2235]

;section 0 Span:0..31
;Mol Carcinog  1991;4(3):196-202
(SEC
  (FRAG (IN:[0..3] Mol) (NNP:[4..12] Carcinog) (CD:[14..18] 1991)
        (CC:[18..21] ;4-LRB-) (CD:[21..22] 3) (-RRB-:[22..23] -RRB-)
        (CD:[23..27] :196) (::[27..28] -) (CD:[28..31] 202)))

;sentence 1 Span:36..106
;Ras gene mutation and amplification in human nonmelanoma skin cancers.
;[36..39]:gene-rna:"Ras"
;[81..105]:malignancy:"nonmelanoma skin cancers"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[36..39] Ras) (NN:[40..44] gene) (NN:[45..53] mutation))
      (CC:[54..57] and)
      (NP (NN:[58..71] amplification)))
    (PP (IN:[72..74] in)
      (NP (JJ:[75..80] human)
         (NN:[81..92] nonmelanoma) (NN:[93..97] skin) (NNS:[98..105] cancers)))
    (.:[105..106] .)))

;section 2 Span:110..181
;Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN.
(SEC
  (FRAG (NNP:[110..119] Pierceall) (NNP:[120..122] WE) (,:[122..123] ,)
        (NNP:[124..132] Goldberg) (NNS:[133..135] LH) (,:[135..136] ,)
        (NNP:[137..144] Tainsky) (NNP:[145..147] MA) (,:[147..148] ,)
        (NNP:[149..161] Mukhopadhyay) (NNP:[162..163] T) (,:[163..164] ,)
        (NNP:[165..177] Ananthaswamy) (NNP:[178..181] HN.)))

;section 3 Span:185..276
;Department of Immunology, University of Texas M. D. Anderson Cancer Center, 
;Houston 77030.
(SEC
  (FRAG (NNP:[185..195] Department) (IN:[196..198] of)
        (NNP:[199..209] Immunology) (,:[209..210] ,) (NNP:[211..221] University)
        (IN:[222..224] of) (NNP:[225..230] Texas) (NNP:[231..233] M.)
        (NNP:[234..236] D.) (NNP:[237..245] Anderson) (NNP:[246..252] Cancer)
        (NNP:[253..259] Center) (,:[259..260] ,) (NNP:[262..269] Houston)
        (VBD:[270..275] 77030) (.:[275..276] .)))

;sentence 4 Span:280..500
;Our previous studies have shown that human skin cancers occurring on
;sun-exposed  body sites frequently contain activated Ha-ras oncogenes capable
;of inducing  morphologic and tumorigenic transformation of NIH 3T3 cells.
;[323..372]:malignancy:"skin cancers occurring on sun-exposed  body sites"
;[402..408]:gene-rna:"Ha-ras"
(SENT
  (S
    (NP-SBJ (PRP$:[280..283] Our) (JJ:[284..292] previous)
            (NNS:[293..300] studies))
    (VP (VBP:[301..305] have)
      (VP (VBN:[306..311] shown)
        (SBAR (IN:[312..316] that)
          (S
            (NP-SBJ
              (NP (JJ:[317..322] human) (NN:[323..327] skin)
                  (NNS:[328..335] cancers))
              (VP (VBG:[336..345] occurring)
                (PP (IN:[346..348] on)
                  (NP
                    (ADJP (NN:[349..352] sun) (HYPH:[352..353] -)
                          (VBN:[353..360] exposed))
                    (NN:[362..366] body) (NNS:[367..372] sites)))))
            (ADVP (RB:[373..383] frequently))
            (VP (VBP:[384..391] contain)
              (NP
                (NP (JJ:[392..401] activated) (NN:[402..408] Ha-ras)
                    (NNS:[409..418] oncogenes))
                (ADJP (JJ:[419..426] capable)
                  (PP (IN:[427..429] of)
                    (VP (VBG:[430..438] inducing)
                      (NP
                        (NP
                          (NP (JJ:[440..451] morphologic)
                            (NML-1 (-NONE-:[451..451] *P*)))
                          (CC:[452..455] and)
                          (NP (JJ:[456..467] tumorigenic)
                            (NML-1 (NN:[468..482] transformation))))
                        (PP (IN:[483..485] of)
                          (NP (NN:[486..489] NIH) (NN:[490..493] 3T3)
                              (NNS:[494..499] cells)))))))))))))
    (.:[499..500] .)))

;sentence 5 Span:501..916
;In this study, we  analyzed human primary squamous cell carcinomas (SCCs) and
;basal cell carcinomas  (BCCs) occurring on sun-exposed body sites for
;mutations in codons 12, 13, and  61 of Ha-ras, Ki-ras, and N-ras oncogenes by
;amplification of genomic tumor DNAs  by the polymerase chain reaction,
;followed by dot-blot hybridization to  synthetic oligonucleotide probes
;designed to detect single base-pair mutations.
;[535..567]:malignancy:"primary squamous cell carcinomas"
;[569..573]:malignancy:"SCCs"
;[579..644]:malignancy:"basal cell carcinomas  (BCCs) occurring on sun-exposed
;body sites"
;[649..658]:variation-event:"mutations"
;[662..671]:variation-location:"codons 12"
;[673..675]:variation-location:"13"
;[682..684]:variation-location:"61"
;[688..694]:gene-rna:"Ha-ras"
;[696..702]:gene-rna:"Ki-ras"
;[708..713]:gene-rna:"N-ras"
;[771..781]:gene-protein:"polymerase"
;[889..915]:variation-type:"single base-pair mutations"
(SENT
  (S
    (PP (IN:[501..503] In)
      (NP (DT:[504..508] this) (NN:[509..514] study)))
    (,:[514..515] ,)
    (NP-SBJ (PRP:[516..518] we))
    (VP (VBD:[520..528] analyzed)
      (NP
        (NP
          (NP
            (ADJP-2 (JJ:[529..534] human))
            (ADJP-1 (JJ:[535..542] primary))
            (NML
              (NML (JJ:[543..551] squamous) (NN:[552..556] cell)
                   (NNS:[557..567] carcinomas))
              (NML (-LRB-:[568..569] -LRB-) (NNS:[569..573] SCCs)
                   (-RRB-:[573..574] -RRB-))))
          (CC:[575..578] and)
          (NP
            (ADJP-2 (-NONE-:[578..578] *P*))
            (ADJP-1 (-NONE-:[578..578] *P*))
            (NML
              (NML (JJ:[579..584] basal) (NN:[585..589] cell)
                   (NNS:[590..600] carcinomas))
              (NML (-LRB-:[602..603] -LRB-) (NNS:[603..607] BCCs)
                   (-RRB-:[607..608] -RRB-)))))
        (VP (VBG:[609..618] occurring)
          (PP-LOC (IN:[619..621] on)
            (NP
              (ADJP (NN:[622..625] sun) (HYPH:[625..626] -)
                    (VBN:[626..633] exposed))
              (NN:[634..638] body) (NNS:[639..644] sites)))))
      (PP (IN:[645..648] for)
        (NP
          (NP (NNS:[649..658] mutations))
          (PP-LOC (IN:[659..661] in)
            (NP
              (NP
                (NP
                  (NML-3 (NNS:[662..668] codons))
                  (CD:[669..671] 12))
                (,:[671..672] ,)
                (NP
                  (NML-3 (-NONE-:[672..672] *P*))
                  (CD:[673..675] 13))
                (,:[675..676] ,) (CC:[677..680] and)
                (NP
                  (NML-3 (-NONE-:[680..680] *P*))
                  (CD:[682..684] 61)))
              (PP (IN:[685..687] of)
                (NP
                  (NP (NN:[688..694] Ha-ras)
                    (NML-4 (-NONE-:[694..694] *P*)))
                  (,:[694..695] ,)
                  (NP (NN:[696..702] Ki-ras)
                    (NML-4 (-NONE-:[702..702] *P*)))
                  (,:[702..703] ,) (CC:[704..707] and)
                  (NP (NN:[708..713] N-ras)
                    (NML-4 (NNS:[714..723] oncogenes)))))))))
      (PP (IN:[724..726] by)
        (NP
          (NP (NN:[727..740] amplification))
          (PP (IN:[741..743] of)
            (NP (JJ:[744..751] genomic) (NN:[752..757] tumor)
                (NNS:[758..762] DNAs)))
          (PP (IN:[764..766] by)
            (NP (DT:[767..770] the) (NN:[771..781] polymerase)
                (NN:[782..787] chain) (NN:[788..796] reaction)))))
      (,:[796..797] ,)
      (S-ADV
        (NP-SBJ-5 (-NONE-:[797..797] *))
        (VP (VBN:[798..806] followed)
          (NP-5 (-NONE-:[806..806] *))
          (PP (IN:[807..809] by)
            (NP-LGS
              (NP
                (NML (NN:[810..813] dot) (HYPH:[813..814] -)
                     (NN:[814..818] blot))
                (NN:[819..832] hybridization))
              (PP (TO:[833..835] to)
                (NP
                  (NP (JJ:[837..846] synthetic) (NN:[847..862] oligonucleotide)
                      (NNS:[863..869] probes))
                  (VP (VBN:[870..878] designed)
                    (S
                      (NP-SBJ (-NONE-:[878..878] *))
                      (VP (TO:[879..881] to)
                        (VP (VB:[882..888] detect)
                          (NP (JJ:[889..895] single)
                            (NML (NN:[896..900] base) (HYPH:[900..901] -)
                                 (NN:[901..905] pair))
                            (NNS:[906..915] mutations)))))))))))))
    (.:[915..916] .)))

;sentence 6 Span:918..1058
;In addition to the primary human skin cancers, we also analyzed
;Ha-ras-positive  NIH 3T3 transformants for mutations in the Ha-ras oncogene.
;[937..963]:malignancy:"primary human skin cancers"
;[982..1020]:malignancy:"Ha-ras-positive  NIH 3T3 transformants"
;[982..988]:gene-rna:"Ha-ras"
;[1042..1048]:gene-rna:"Ha-ras"
(SENT
  (S
    (PP (IN:[918..920] In)
      (NP
        (NP (NN:[921..929] addition))
        (PP (TO:[930..932] to)
          (NP (DT:[933..936] the)
             (JJ:[937..944] primary) (JJ:[945..950] human) (NN:[951..955] skin)
             (NNS:[956..963] cancers)))))
    (,:[963..964] ,)
    (NP-SBJ (PRP:[965..967] we))
    (VP
      (ADVP (RB:[968..972] also))
      (VBD:[973..981] analyzed)
      (NP
        (ADJP (NN:[982..988] Ha-ras) (HYPH:[988..989] -)
              (JJ:[989..997] positive))
        (NML (NN:[999..1002] NIH) (NN:[1003..1006] 3T3))
        (NNS:[1007..1020] transformants))
      (PP (IN:[1021..1024] for)
        (NP
          (NP (NNS:[1025..1034] mutations))
          (PP (IN:[1035..1037] in)
            (NP (DT:[1038..1041] the) (NN:[1042..1048] Ha-ras)
                (NN:[1049..1057] oncogene))))))
    (.:[1057..1058] .)))

;sentence 7 Span:1059..1468
;The results  indicated that all three NIH 3T3 transformants, 11 of 24 (46%)
;SCCs, and 5 of 16  (31%) BCCs contained mutations at the second position of
;Ha-ras codon 12  (GGC----GTC), predicting a glycine-to-valine amino acid
;substitution, whereas  only 1 of 40 skin cancers (an SCC) displayed a
;mutation in the first position of  Ki-ras codon 12 (GGT----AGT), predicting a
;glycine-to-serine amino acid change.
;[1097..1118]:malignancy:"NIH 3T3 transformants"
;[1135..1139]:malignancy:"SCCs"
;[1160..1164]:malignancy:"BCCs"
;[1175..1184]:variation-event:"mutations"
;[1192..1207]:variation-location:"second position"
;[1211..1217]:gene-rna:"Ha-ras"
;[1218..1226]:variation-location:"codon 12"
;[1229..1232]:variation-state-original:"GGC"
;[1236..1239]:variation-state-altered:"GTC"
;[1255..1262]:variation-state-original:"glycine"
;[1266..1272]:variation-state-altered:"valine"
;[1273..1296]:variation-type:"amino acid substitution"
;[1320..1332]:malignancy:"skin cancers"
;[1337..1340]:malignancy:"SCC"
;[1354..1362]:variation-event:"mutation"
;[1370..1384]:variation-location:"first position"
;[1389..1395]:gene-rna:"Ki-ras"
;[1396..1404]:variation-location:"codon 12"
;[1406..1409]:variation-state-original:"GGT"
;[1413..1416]:variation-state-altered:"AGT"
;[1432..1439]:variation-state-original:"glycine"
;[1443..1449]:variation-state-altered:"serine"
;[1450..1467]:variation-type:"amino acid change"
(SENT
  (S
    (NP-SBJ (DT:[1059..1062] The) (NNS:[1063..1070] results))
    (VP (VBD:[1072..1081] indicated)
      (SBAR (IN:[1082..1086] that)
        (S
          (NP-SBJ
            (NP (DT:[1087..1090] all) (CD:[1091..1096] three)
              
              (NML (NN:[1097..1100] NIH) (NN:[1101..1104] 3T3))
              (NNS:[1105..1118] transformants))
            (,:[1118..1119] ,)
            (NP
              (NP (CD:[1120..1122] 11))
              (PP (IN:[1123..1125] of)
                (NP (CD:[1126..1128] 24)
                  (PRN (-LRB-:[1129..1130] -LRB-)
                    (NP (CD:[1130..1132] 46) (NN:[1132..1133] %))
                    (-RRB-:[1133..1134] -RRB-))
                  (NNS:[1135..1139] SCCs))))
            (,:[1139..1140] ,) (CC:[1141..1144] and)
            (NP
              (NP (CD:[1145..1146] 5))
              (PP (IN:[1147..1149] of)
                (NP (CD:[1150..1152] 16)
                  (PRN (-LRB-:[1154..1155] -LRB-)
                    (NP (CD:[1155..1157] 31) (NN:[1157..1158] %))
                    (-RRB-:[1158..1159] -RRB-))
                  (NNS:[1160..1164] BCCs)))))
          (VP (VBD:[1165..1174] contained)
            (NP
              (NP (NNS:[1175..1184] mutations))
              (PP-LOC (IN:[1185..1187] at)
                (NP
                  (NP (DT:[1188..1191] the)
                     (JJ:[1192..1198] second) (NN:[1199..1207] position))
                  (PP (IN:[1208..1210] of)
                    (NP (NN:[1211..1217] Ha-ras)
                       (NN:[1218..1223] codon) (CD:[1224..1226] 12)
                      (PRN (-LRB-:[1228..1229] -LRB-)
                        (NP
                          (NP (NN:[1229..1232] GGC))
                          (PP (SYM:[1232..1236] ----)
                            (NP (NN:[1236..1239] GTC))))
                        (-RRB-:[1239..1240] -RRB-)))))))
            (,:[1240..1241] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[1241..1241] *))
              (VP (VBG:[1242..1252] predicting)
                (NP (DT:[1253..1254] a)
                  (NML
                    (NML (NN:[1255..1262] glycine))
                    (HYPH:[1262..1263] -)
                    (PP (TO:[1263..1265] to) (HYPH:[1265..1266] -)
                      (NP (NN:[1266..1272] valine))))
                  (NP
                    (NML (JJ:[1273..1278] amino) (NN:[1279..1283] acid))
                    (NN:[1284..1296] substitution)))))
            (,:[1296..1297] ,)
            (SBAR-ADV (IN:[1298..1305] whereas)
              (S
                (NP-SBJ
                  (NP
                    (ADVP (RB:[1307..1311] only))
                    (CD:[1312..1313] 1))
                  (PP (IN:[1314..1316] of)
                    (NP (CD:[1317..1319] 40)
                       (NN:[1320..1324] skin) (NNS:[1325..1332] cancers)))
                  (PRN (-LRB-:[1333..1334] -LRB-)
                    (NP (DT:[1334..1336] an) (NN:[1337..1340] SCC))
                    (-RRB-:[1340..1341] -RRB-)))
                (VP (VBD:[1342..1351] displayed)
                  (NP (DT:[1352..1353] a) (NN:[1354..1362] mutation))
                  (PP-LOC (IN:[1363..1365] in)
                    (NP
                      (NP (DT:[1366..1369] the)
                         (JJ:[1370..1375] first) (NN:[1376..1384] position))
                      (PP (IN:[1385..1387] of)
                        (NP (NN:[1389..1395] Ki-ras)
                           (NN:[1396..1401] codon) (CD:[1402..1404] 12)
                          (PRN (-LRB-:[1405..1406] -LRB-)
                            (NP
                              (NP (NN:[1406..1409] GGT))
                              (PP (SYM:[1409..1413] ----)
                                (NP (NN:[1413..1416] AGT))))
                            (-RRB-:[1416..1417] -RRB-))))))
                  (,:[1417..1418] ,)
                  (S-ADV
                    (NP-SBJ (-NONE-:[1418..1418] *))
                    (VP (VBG:[1419..1429] predicting)
                      (NP (DT:[1430..1431] a)
                        (NML
                          (NML (NN:[1432..1439] glycine))
                          (HYPH:[1439..1440] -)
                          (PP (TO:[1440..1442] to)
                            (NP (HYPH:[1442..1443] -) (NN:[1443..1449] serine))))
                        
                        (NML (JJ:[1450..1455] amino) (NN:[1456..1460] acid))
                        (NN:[1461..1467] change)))))))))))
    (.:[1467..1468] .)))

;sentence 8 Span:1470..1579
;In addition, three of the SCCs contained highly amplified copies of the N-ras
; oncogene in their genomic DNA.
;[1496..1500]:malignancy:"SCCs"
;[1542..1547]:gene-rna:"N-ras"
(SENT
  (S
    (PP (IN:[1470..1472] In)
      (NP (NN:[1473..1481] addition)))
    (,:[1481..1482] ,)
    (NP-SBJ
      (NP (CD:[1483..1488] three))
      (PP (IN:[1489..1491] of)
        (NP (DT:[1492..1495] the) (NNS:[1496..1500] SCCs))))
    (VP (VBD:[1501..1510] contained)
      (NP
        (NP
          (ADJP (RB:[1511..1517] highly) (JJ:[1518..1527] amplified))
          (NNS:[1528..1534] copies))
        (PP (IN:[1535..1537] of)
          (NP (DT:[1538..1541] the) (NN:[1542..1547] N-ras)
              (NN:[1549..1557] oncogene))))
      (PP-LOC (IN:[1558..1560] in)
        (NP (PRP$:[1561..1566] their) (JJ:[1567..1574] genomic)
            (NN:[1575..1578] DNA))))
    (.:[1578..1579] .)))

;sentence 9 Span:1580..1711
;Interestingly, two of the SCCs containing  amplified N-ras sequences also had
;G----T mutations in codon 12 of the Ha-ras  oncogene.
;[1606..1610]:malignancy:"SCCs"
;[1633..1638]:gene-rna:"N-ras"
;[1658..1659]:variation-state-original:"G"
;[1663..1664]:variation-state-altered:"T"
;[1665..1674]:variation-event:"mutations"
;[1678..1686]:variation-location:"codon 12"
;[1694..1700]:gene-rna:"Ha-ras"
(SENT
  (S
    (ADVP (RB:[1580..1593] Interestingly))
    (,:[1593..1594] ,)
    (NP-SBJ
      (NP (CD:[1595..1598] two))
      (PP (IN:[1599..1601] of)
        (NP
          (NP (DT:[1602..1605] the) (NNS:[1606..1610] SCCs))
          (VP (VBG:[1611..1621] containing)
            (NP (JJ:[1623..1632] amplified) (NN:[1633..1638] N-ras)
                (NNS:[1639..1648] sequences))))))
    (ADVP (RB:[1649..1653] also))
    (VP (VBD:[1654..1657] had)
      (NP
        (NML
          (NML (NN:[1658..1659] G))
          (PP (SYM:[1659..1663] ----)
            (NP (NN:[1663..1664] T))))
        (NNS:[1665..1674] mutations))
      (PP-LOC (IN:[1675..1677] in)
        (NP
          (NP (NN:[1678..1683] codon) (CD:[1684..1686] 12))
          (PP (IN:[1687..1689] of)
            (NP (DT:[1690..1693] the) (NN:[1694..1700] Ha-ras)
                (NN:[1702..1710] oncogene))))))
    (.:[1710..1711] .)))

;sentence 10 Span:1712..1974
;These studies demonstrate that mutations in codon 12 of the Ha-ras  oncogene
;occurred at a high frequency in human skin cancers originating on 
;sun-exposed body sites, whereas mutation in codon 12 of Ki-ras or
;amplification  of N-ras occurred at a low frequency.
;[1743..1752]:variation-event:"mutations"
;[1756..1764]:variation-location:"codon 12"
;[1772..1778]:gene-rna:"Ha-ras"
;[1827..1878]:malignancy:"skin cancers originating on  sun-exposed body
;sites"
;[1888..1896]:variation-event:"mutation"
;[1900..1908]:variation-location:"codon 12"
;[1912..1918]:gene-rna:"Ki-ras"
;[1940..1945]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ (DT:[1712..1717] These) (NNS:[1718..1725] studies))
    (VP (VBP:[1726..1737] demonstrate)
      (SBAR (IN:[1738..1742] that)
        (S
          (NP-SBJ
            (NP (NNS:[1743..1752] mutations))
            (PP-LOC (IN:[1753..1755] in)
              (NP
                (NP (NN:[1756..1761] codon) (CD:[1762..1764] 12))
                (PP (IN:[1765..1767] of)
                  (NP (DT:[1768..1771] the) (NN:[1772..1778] Ha-ras)
                      (NN:[1780..1788] oncogene))))))
          (VP (VBD:[1789..1797] occurred)
            (PP (IN:[1798..1800] at)
              (NP (DT:[1801..1802] a) (JJ:[1803..1807] high)
                  (NN:[1808..1817] frequency)))
            (PP (IN:[1818..1820] in)
              (NP
                (NP (JJ:[1821..1826] human) (NN:[1827..1831] skin)
                    (NNS:[1832..1839] cancers))
                (VP (VBG:[1840..1851] originating)
                  (PP (IN:[1852..1854] on)
                    (NP
                      (ADJP (NN:[1856..1859] sun) (HYPH:[1859..1860] -)
                            (VBN:[1860..1867] exposed))
                      (NN:[1868..1872] body) (NNS:[1873..1878] sites))))))
            (,:[1878..1879] ,)
            (SBAR-ADV (IN:[1880..1887] whereas)
              (S
                (NP-SBJ
                  (NP
                    (NP (NN:[1888..1896] mutation))
                    (PP-LOC (IN:[1897..1899] in)
                      (NP
                        (NP (NN:[1900..1905] codon) (CD:[1906..1908] 12))
                        (PP (IN:[1909..1911] of)
                          (NP (NN:[1912..1918] Ki-ras))))))
                  (CC:[1919..1921] or)
                  (NP
                    (NP (NN:[1922..1935] amplification))
                    (PP (IN:[1937..1939] of)
                      (NP (NN:[1940..1945] N-ras)))))
                (VP (VBD:[1946..1954] occurred)
                  (PP (IN:[1955..1957] at)
                    (NP (DT:[1958..1959] a) (JJ:[1960..1963] low)
                        (NN:[1964..1973] frequency))))))))))
    (.:[1973..1974] .)))

;sentence 11 Span:1975..2187
;Since the mutations in the Ha-ras and  Ki-ras oncogenes were located opposite
;potential pyrimidine dimer sites (C-C),  it is likely that these mutations
;were induced by ultraviolet radiation present  in sunlight.
;[1985..1994]:variation-event:"mutations"
;[2002..2008]:gene-rna:"Ha-ras"
;[2014..2020]:gene-rna:"Ki-ras"
;[2063..2079]:variation-type:"pyrimidine dimer"
;[2112..2127]:variation-event:"these mutations"
(SENT
  (S
    (SBAR-ADV (IN:[1975..1980] Since)
      (S
        (NP-SBJ-2
          (NP (DT:[1981..1984] the) (NNS:[1985..1994] mutations))
          (PP (IN:[1995..1997] in)
            (NP (DT:[1998..2001] the)
              (NML
                (NML (NN:[2002..2008] Ha-ras)
                  (NML-1 (-NONE-:[2008..2008] *P*)))
                (CC:[2009..2012] and)
                (NML (NN:[2014..2020] Ki-ras)
                  (NML-1 (NNS:[2021..2030] oncogenes)))))))
        (VP (VBD:[2031..2035] were)
          (VP (VBN:[2036..2043] located)
            (NP-2 (-NONE-:[2043..2043] *))
            (ADVP (RB:[2044..2052] opposite))
            (NP (JJ:[2053..2062] potential)
               (NN:[2063..2073] pyrimidine) (NN:[2074..2079] dimer)
              (NNS:[2080..2085] sites))
            (PRN (-LRB-:[2086..2087] -LRB-)
              (NP (NN:[2087..2088] C) (HYPH:[2088..2089] -) (NN:[2089..2090] C))
              (-RRB-:[2090..2091] -RRB-))))))
    (,:[2091..2092] ,)
    (NP-SBJ (PRP:[2094..2096] it))
    (VP (VBZ:[2097..2099] is)
      (ADJP-PRD (JJ:[2100..2106] likely)
        (SBAR (IN:[2107..2111] that)
          (S
            (NP-SBJ-3 (DT:[2112..2117] these) (NNS:[2118..2127] mutations))
            (VP (VBD:[2128..2132] were)
              (VP (VBN:[2133..2140] induced)
                (NP-3 (-NONE-:[2140..2140] *))
                (PP (IN:[2141..2143] by)
                  (NP-LGS
                    (NP (JJ:[2144..2155] ultraviolet)
                        (NN:[2156..2165] radiation))
                    (ADJP (JJ:[2166..2173] present)
                      (PP (IN:[2175..2177] in)
                        (NP (NN:[2178..2186] sunlight))))))))))))
    (.:[2186..2187] .)))

;section 12 Span:2191..2235
;PMID: 2064725 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2191..2195] PMID) (::[2195..2196] :) (CD:[2197..2204] 2064725)
        (NN:[2205..2206] -LSB-) (NNP:[2206..2212] PubMed) (::[2213..2214] -)
        (NN:[2215..2222] indexed) (IN:[2223..2226] for)
        (NNP:[2227..2235] MEDLINE-RSB-)))
